Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CFD | P00746 | 13/20 | 0.39 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29544790 | 0.91 | HPGD (0.40) | HPGDCFDKIF18ACHRNB2CHRNA4 | |
| SCHEMBL18591200 | 0.91 | CHRNB2 (0.41) | HPGDCFDKIF18ACHRNB2CHRNA4 | |
| SCHEMBL18555528 | 0.91 | HPGD (0.40) | HPGDCFDKIF18ACHRNB2CHRNA4 | |
| SCHEMBL18591123 | 0.87 | HPGD (0.42) | HPGDCFDCHRNB2CHRNA4GRM5 | |
| SCHEMBL18555243 | 0.87 | CHRNB2 (0.38) | HPGDCFDCHRNB2CHRNA4GRM5 | |
| SCHEMBL18555137 | 0.87 | CFD (0.38) | HPGDCFDKIF18ACHRNB2CHRNA4 | |
| SCHEMBL29545063 | 0.87 | CFD (0.38) | HPGDCFDKIF18ACHRNB2CHRNA4 | |
| SCHEMBL18578527 | 0.87 | CFD (0.38) | HPGDCFDKIF18ACHRNB2CHRNA4 | |
| SCHEMBL18554981 | 0.85 | HPGD (0.40) | HPGDCFDKIF18ACHRNB2CHRNA4 | |
| SCHEMBL30052100 | 0.85 | HPGD (0.40) | HPGDCFDKIF18ACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | CFD, F12, F3 | HPGD 380/4885CFD 1/4885KIF18A 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.